Faeth Therapeutics FTH 深 沪
等待开盘 09-04 09:30:00 美东时间
39.00
-0.120
-0.31%
华盛通- 最 高39.655
- 今 开38.90
- 成交量 17.52万股
- 最 低 37.371
- 昨 收 39.12
- 总市值 10.08亿
- 52周最高 40.89
- 市盈率 静 --
- 换手率 0.68%
- 52周最低 7.45
- 委 比 -6.98%
- 总股本 2584.04万
- 历史最高 530.00
- 量 比 0.58
- 振 幅 5.84%
- 历史最低 5.00
- 每 手 1
- 风险率 9.75%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 罗斯百货、迪尔股份获多家大行上调目标价；沃尔玛、Advance遭多家大行下调目标价
今日重点评级关注：摩根士丹利：维持Ultragenyx Pharmaceutical"超配"评级，目标价从67美元升至74美元；Truist Securities：维持Solid Biosciences"买入"评级，目标价从16美元升至20美元
08-24 16:40
Faeth Therapeutics Says FDA Grants Fast Track Designation To Combination Of Sapanisertib And Serabelisib With Paclitaxel For Treatment Of Patients With Endometrial Cancer
— Fast Track designation applies to sapanisertib and serabelisib (PIKTOR) in combination with paclitaxel for the treatment of patients with advanced or recurrent endometrial cancer whose tumors harbor a PI3K/AKT/mTOR pathway alteration — Faeth expects topline data from its ongoing Phase 2 trial in s...
08-17 19:33
美股大行评级 | 潜在涨幅207.38%！Truist Securities上调AbCellera Biologics目标价至30美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持AbCellera Biologics"买入"评级，目标价从12美元升至30美元；Stifel：维持Proficient Auto Logistics"买入"评级，目标价从9美元升至12美元
08-12 08:45
Faeth Therapeutics To Present Translational Data And Pharmacokinetic/Pharmacodynamic Analysis For PIKTOR, Oral Combination Of Serabelisib And Sapanisertib, At 2026 Summit For STOP Cancer
— The data will be presented at the 2026 Summit for Novel Therapeutics in Oncology and Precision Medicine in Cancer conference on August 8 — These data collectively informed PIKTOR dose selection in the ongoing Phase 2 trial in second-line advanced endometrial cancer (Study FTH-PIK-201) Faeth Therap...
08-07 19:35
Faeth Therapeutics Q2 EPS $(2.84) Beats $(3.29) Estimate
Faeth Therapeutics (NASDAQ:FTH) reported quarterly losses of $(2.84) per share which beat the analyst consensus estimate of $(3.29) by 13.68 percent. This is a 27.37 percent increase over losses of $(3.91) per share from the same period last year.
08-04 19:34
美股大行评级 | 最高400美元！亚马逊绩后获11家大行上调目标价；苹果绩后评级分歧大！3家上调，3家下调；德康医疗、万事达、神经分泌生物科学获多家大行上调目标价
今日重点评级关注：TD Cowen：维持加拿大鹅"买入"评级，目标价从13美元升至18美元；瑞银：维持吉登运动服"买入"评级，目标价从110美元升至111美元
08-03 11:38
美股大行评级 | 潜在涨幅129.15%！HC Wainwright & Co.升Q32 Bio(QTTB)目标价至36美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Q32 Bio"买入"评级，目标价从13美元升至36美元；Chardan Capital：维持ProMIS Neurosciences"买入"评级，目标价从20美元升至33美元
07-29 11:37
Oppenheimer Initiates Coverage On Faeth Therapeutics with Outperform Rating, Announces Price Target of $60
Oppenheimer analyst Jay Olson initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Outperform rating and announces Price Target of $60.
07-28 17:26
美股大行评级 | 伯恩斯坦上调Robinhood目标价从130美元升至160美元；纽约梅隆银行、Datadog、五三银行、旅行者财产险集团获多家机构上调评级
今日重点评级关注：Needham：维持Immuneering"买入"评级，目标价从11美元升至18美元；富瑞：维持塞德斯医疗"买入"评级，目标价从90美元升至100美元
07-21 11:36
美股大行评级 | 阿斯麦、贝莱德、纽约梅隆银行、信达思、JB亨特运输服务、美国制商银行、PNC金融服务集团等获多家大行集体上调目标价
今日重点评级关注：瑞杰金融：维持Electrovaya"强力买入"评级，目标价从14美元升至22美元；BTIG：维持vTv Therapeutics"买入"评级，目标价从49美元升至57美元
07-17 11:35
